Literature DB >> 2156055

Apparent affinity of opioid antagonists in morphine-treated rhesus monkeys discriminating between saline and naltrexone.

C P France1, B R de Costa, A E Jacobson, K C Rice, J H Woods.   

Abstract

In morphine-treated (3.2 mg/kg/day) rhesus monkeys discriminating between s.c. injections of 0.01 mg/kg of naltrexone and saline while responding under a fixed-ratio schedule of stimulus-shock termination, the apparent affinity of antagonists for opioid receptors was estimated using two different methods: 1) substitution studies in which cumulative doses of drug were administered to monkeys that received morphine 3 hr before the session and 2) studies in which single doses of antagonists were administered before cumulative doses of agonists in monkeys that had received saline 3 hr before the session. The ED50 values from the substitution study were compared to apparent pA2 values determined when antagonists were administered before agonists. Apparent affinities (pA2) for antagonists, estimated by their capacity to prevent the effects of the opioid agonist alfentanil, were: naltrexone = 8.69, naloxone = 7.78, quadazocine = 7.55, nalorphine = 7.31 and naltrindole = 5.29. The pA2 values were highly correlated (r = 0.94) with ED50 values determined in substitution studies. These results demonstrate that substitution by opioid antagonists for the naltrexone discriminative stimulus in morphine-treated monkeys provides a good estimate of affinity for opioid mu receptors as supported by independent pA2 analyses. These data also suggest affinity of opioid antagonists for opioid mu receptors is not changed in monkeys treated daily with 3.2 mg/kg of morphine and, furthermore, support the notion that binding to opioid receptors is the mechanism, by which antagonists precipitate withdrawal in opioid-dependent monkeys.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2156055

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  11 in total

1.  Pharmacological profile of a potent, efficacious fentanyl derivative in rhesus monkeys.

Authors:  C P France; G Winger; M R Seggel; K C Rice; J H Woods
Journal:  Psychopharmacology (Berl)       Date:  1992       Impact factor: 4.530

2.  Differentiation of kappa opioid agonist-induced antinociception by naltrexone apparent pA2 analysis in rhesus monkeys.

Authors:  M C Ko; E R Butelman; J R Traynor; J H Woods
Journal:  J Pharmacol Exp Ther       Date:  1998-05       Impact factor: 4.030

3.  In vivo apparent pA2 analysis in rats treated with either clocinnamox or morphine.

Authors:  E A Walker; T M Richardson; A M Young
Journal:  Psychopharmacology (Berl)       Date:  1996-05       Impact factor: 4.530

4.  Comparison of dehydroepiandrosterone (DHEA) and pregnanolone with existing pharmacotherapies for alcohol abuse on ethanol- and food-maintained responding in male rats.

Authors:  Mary W Hulin; Michelle N Lawrence; Russell J Amato; Peter F Weed; Peter J Winsauer
Journal:  Alcohol       Date:  2015-01-06       Impact factor: 2.405

5.  Cannabinoid Antagonist Drug Discrimination in Nonhuman Primates.

Authors:  Brian D Kangas; Ani S Zakarian; Kiran Vemuri; Shakiru O Alapafuja; Shan Jiang; Spyros P Nikas; Alexandros Makriyannis; Jack Bergman
Journal:  J Pharmacol Exp Ther       Date:  2019-10-22       Impact factor: 4.030

6.  Reversal and Prevention of the Respiratory-Depressant Effects of Heroin by the Novel μ-Opioid Receptor Antagonist Methocinnamox in Rhesus Monkeys.

Authors:  Lisa R Gerak; David R Maguire; James H Woods; Stephen M Husbands; Alex Disney; Charles P France
Journal:  J Pharmacol Exp Ther       Date:  2018-11-21       Impact factor: 4.030

7.  Comparison of naltrexone, 6alpha-naltrexol, and 6beta-naltrexol in morphine-dependent and in nondependent rhesus monkeys.

Authors:  Jun-Xu Li; Lance R McMahon; Charles P France
Journal:  Psychopharmacology (Berl)       Date:  2007-09-16       Impact factor: 4.530

8.  Discriminative stimulus effects of 1-(2,5-dimethoxy-4-methylphenyl)-2-aminopropane in rhesus monkeys: antagonism and apparent pA2 analyses.

Authors:  Jun-Xu Li; Kenner C Rice; Charles P France
Journal:  J Pharmacol Exp Ther       Date:  2008-12-19       Impact factor: 4.030

Review 9.  Buprenorphine maintenance and mu-opioid receptor availability in the treatment of opioid use disorder: implications for clinical use and policy.

Authors:  Mark K Greenwald; Sandra D Comer; David A Fiellin
Journal:  Drug Alcohol Depend       Date:  2014-08-19       Impact factor: 4.492

10.  Interactions between Delta(9)-tetrahydrocannabinol and mu opioid receptor agonists in rhesus monkeys: discrimination and antinociception.

Authors:  Jun-Xu Li; Lance R McMahon; Lisa R Gerak; Ginger L Becker; Charles P France
Journal:  Psychopharmacology (Berl)       Date:  2008-05-10       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.